Perrigo Boosts R&D Spending, Focuses On Quality Control
This article was originally published in The Tan Sheet
Executive Summary
Perrigo plans to increase R&D spending in the second half of FY 2001 pending a favorable FDA follow-up manufacturing audit of the firm's Allegan, Mich. facility, President & CEO David Gibbons told analysts during a conference call Jan. 23.
You may also be interested in...
Lower Manufacturing Costs Integral To Perrigo 2003 Strategy, CEO Says
One of Perrigo's primary goals for the coming fiscal year will be to reduce its manufacturing expenditures and improve its "low-cost supplier position.
Perrigo Indication-Specific Analgesics Slated For Mid-2001 Launch
Perrigo plans to launch a Women's Menstrual Relief analgesic in April, comparable to McNeil Consumer Healthcare's Women's Tylenol, which debuted in October.
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.